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Early-onset primary antibody 
deficiency resembling common 
variable immunodeficiency 
challenges the diagnosis of 
Wiedeman-Steiner and Roifman 
syndromes
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Bart N. Lambrecht4,5,11, Frans De Baets2, Sergio D. Rosenzweig6, Elfride De Baere3 & Filomeen 
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Syndromic primary immunodeficiencies are rare genetic disorders that affect both the immune 
system and other organ systems. More often, the immune defect is not the major clinical problem 
and is sometimes only recognized after a diagnosis has been made based on extra-immunological 
abnormalities. Here, we report two sibling pairs with syndromic primary immunodeficiencies that 
exceptionally presented with a phenotype resembling early-onset common variable immunodeficiency, 
while extra-immunological characteristics were not apparent at that time. Additional features not 
typically associated with common variable immunodeficiency were diagnosed only later, including 
skeletal and organ anomalies and mild facial dysmorphism. Whole exome sequencing revealed KMT2A-
associated Wiedemann-Steiner syndrome in one sibling pair and their mother. In the other sibling pair, 
targeted testing of the known disease gene for Roifman syndrome (RNU4ATAC) provided a definite 
diagnosis. With this study, we underline the importance of an early-stage and thorough genetic 
assessment in paediatric patients with a common variable immunodeficiency phenotype, to establish 
a conclusive diagnosis and guide patient management. In addition, this study extends the mutational 
and immunophenotypical spectrum of Wiedemann-Steiner and Roifman syndromes and highlights 
potential directions for future pathophysiological research.
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Common variable immunodeficiency (CVID) is one of the most frequently diagnosed primary immunodeficien-
cies (PIDs), and is defined as decreased serum immunoglobulin (Ig) G, decreased IgA and/or IgM, poor antibody 
responses to vaccines, and exclusion of other causes of hypogammaglobulinemia1. Patients commonly experience 
recurrent (sinopulmonary) infections and features of immune dysregulation such as autoimmunity1, 2. About 
25% of CVID patients are diagnosed in childhood3. To rule out transient hypogammaglobulinemia of infancy, in 
which Ig levels spontaneously resolve mostly by the age of two to four years, a definite diagnosis of CVID should 
not be given before the age of four years1.
Here, we report novel familial cases of Wiedemann-Steiner syndrome (WSS) and Roifman syndrome (RS) 
that were initially categorized as early-onset CVID. WSS and RS are rare syndromic PIDs, affecting the immune 
system as well as other organ systems4–6. Although there is considerable phenotypic heterogeneity in both syn-
dromes, hallmark extra-immunological features are generally evident very early in life7, 8. WSS is typically charac-
terized by hypertrichosis cubiti, growth retardation, developmental delay and facial dysmorphism, and is caused 
by heterozygous mutations in lysine methyltransferase 2 A (KMT2A)7, 9–14. KMT2A (also called mixed-lineage 
leukemia, MLL) encodes a histone methyltransferase involved in regulating chromatin-mediated transcription 
and is a frequent target of chromosomal rearrangements in childhood leukemia9, 15. WSS has only been recently 
associated with primary antibody deficiency7. RS, on the other hand, is commonly featured by antibody defi-
ciency as well as growth retardation, spondyloepiphyseal dysplasia and retinal dystrophy8, 16. Biallelic mutations 
in RNU4ATAC, a noncoding small nuclear RNA (snRNA) gene, were recently identified as a cause of RS8. U4atac 
snRNA is an important component of the minor spliceosome required for minor intron splicing8.
This report aspires to increase awareness among immunologists and geneticists that a CVID phenotype can 
be the principal presentation of WSS and RS in early childhood, which is exceptional and has not been previ-
ously reported. The prior diagnosis of early-onset CVID diverted attention away from the initially less evident 
extra-immunological features, which significantly delayed identification of the underlying syndromic disorders. 
Additionally, in both families we identified mutations that have not been previously associated with disease. We 
aimed to provide insight as to how these mutations are disease-causing. Finally, we expand the immunopheno-
typical spectrum of WSS and RS, which could support future mechanistic research.
Results
An early-onset CVID phenotype in two unrelated sibling pairs. This study reports on two unre-
lated sibling pairs with recurrent respiratory tract infections and antibody deficiency categorized as CVID in 
early childhood. The family A monozygotic twin boys (Fig. 1a, II:2 and II:3) were born prematurely at 34 weeks 
Figure 1. Family A with KMT2A-associated Wiedemann-Steiner syndrome (WSS). (a) Pedigree of family A. 
(b) Skipping of KMT2A exon 28. Gel electrophoresis of the KMT2A cDNA region containing exon 28 revealed 
a second shorter transcript in the three affected individuals. HC1 and HC2 represent two healthy controls; 
GAPDH was used as reference target. In-frame deletion of exon 28 was confirmed by cDNA sequencing; c.10755 
and c.10835 indicate the start respectively stop position of exon 28. (c) KMT2A protein domains (adapted from 
ref. 9). KMT2A is cleaved in an N-terminal (KMT2A-N) and C-terminal (KMT2A-C) fragment, which form a 
non-covalently associated complex. Deletion of the amino acids encoded by exon 28 may disrupt the interaction 
site between the two fragments.
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gestational age to non-consanguineous, Belgian parents and are currently 11 years old. One of them (II:3) was 
born with bilateral inguinal hernia and hypospadias, which were attributed to his premature birth. From the first 
year of life, the twin boys suffered from recurrent upper and lower respiratory tract infections, often requiring 
antibiotics. At 2 months of age, patient II:3 developed severe pneumonia with respiratory arrest and heart failure. 
The latter led to the recognition of a patent ductus arteriosus, which was surgically ligated shortly thereafter. The 
postoperative course was complicated by severe respiratory distress requiring ventilation and systemic corticos-
teroids. Upon immunological evaluation, both patients II:2 and II:3 demonstrated panhypogammaglobulinemia, 
poor antibody responses to Pneumococcal polysaccharide vaccine, increased naive B cells, and very low memory 
B cells (Table 1). Additionally, both patients showed evidence of mild bronchiectasis on high-resolution com-
puted tomography (HRCT) scan at 3.5 years of age.
The family B brother and sister pair (Fig. 2a, II:1 and II:2) were born to healthy, non-consanguineous, Belgian 
parents and are currently 17 and 14 years of age respectively. They had recurrent upper and lower respiratory tract 
infections since the age of 18 months (II:1) and 3 years (II:2). The girl (II:2) also had recurrent gastroenteritis in 
early childhood and diffuse atopic eczema since infancy. Similar to the family A sibling pair, they had panhy-
pogammaglobulinemia and poor global antibody responses to Pneumococcal polysaccharide vaccine (Table 2). 
Serotype-specific Pneumococcal antibody responses were not evaluated. In contrast to the family A twins, the 
family B siblings demonstrated severe B cell lymphopenia with normal switched memory B cell percentages and 
increased CD21low B cell levels (Table 2). HRCT scan in patient II:1 at the age of 7.5 years displayed marked bron-
chiectasis, whereas his sister (II:2) only showed discrete bronchiectasis at a similar age.
In both the family A and B sibling pairs, the clinical presentation and laboratory findings in the first years of 
life were reminiscent of a CVID phenotype. All patients are currently doing well under regular Ig replacement 
therapy, antiflogistic maintenance treatment with azithromycin and intermittent inhaled corticosteroids and/or 
short-acting beta-agonists therapy.
Extra-immunological features raised suspicion of syndromic PID. Although both sibling pairs first 
presented with a phenotype resembling CVID, with time they gradually demonstrated additional clinical features 
not typically associated with CVID (Tables 3 and 4). The family A twin boys developed a third degree atrio-
ventricular block for which a pacemaker was implanted at 5 (II:3) and 6.5 (II:2) years of age respectively. In the 
following years, the boys showed increasing evidence of mild intellectual disability. In retrospect, patient II:3 had 
signs of mild developmental delay during the first years of life. Both twins also demonstrated poor weight gain 
and growth retardation, albeit to a limited extent. Around the age of 9 years, dysmorphic facial features became 
more conspicuous (Table 3). Interestingly, the twins’ mother (I:2) had congenital urogenital tract anomalies con-
sisting of a unicornuate uterus and a unique left ovary, fallopian tube and kidney. Moreover, since childhood, 
she had suffered from right unilateral sensorineural hearing loss as well as recurrent sinusitis and bronchitis 
frequently requiring antibiotics. At that time, genetic or immunological testing had never been performed in the 
mother as she deemed herself to be in good general health. The twins’ older brother (II:1) and father (I:1) had an 
uneventful medical history.
Analogously, the boy in family B (II:1) initially displayed subtle syndromic features, such as mild growth 
retardation, that appeared more pronounced over time. At the age of seven years, diverse skeletal abnormalities 
including spondyloepiphyseal dysplasia were detected (Table 4). At the same age, he was also found to have slowly 
progressive retinal dystrophy (Fig. 2b, Panels I-III) with decreased rod function but near-normal cone function 
on full-field flash electroretinography. Antibody deficiency in combination with skeletal and ophthalmological 
features led to the clinical suspicion of RS in the boy. However, his sister (II:2) had no radiographic sings of spon-
dyloepiphyseal or hip dysplasia nor retinal dystrophy. Moreover, RS was originally presumed to be an X-linked 
recessive condition, although no causal gene had been identified16. When the family B girl (II:2) was about 9 years 
old, Gray et al. reported the first female patient with RS, having a skewed X-inactivation and a milder phenotype 
than her affected brother17. Subsequently, we hypothesized that patient II:2 might be a manifesting heterozygote 
of RS, which could be compatible with her milder extra-immunological phenotype at that time.
Cytogenetic and cytogenomic analyses were negative in both sibling pairs. In the family A twins, 
conventional G-banding karyotype, fluorescent in situ hybridization for region 22q11.2 and subtelomeric screen-
ing were normal. Furthermore, microarray-based comparative genomic hybridisation analysis in both sibling 
pairs did not demonstrate copy number variations.
Whole exome sequencing (WES) uncovers WSS in family A. Since no specific genetic syndrome 
was suspected in family A, WES was performed in patient II:2 and both parents. This revealed a heterozygous 
splice site variant in KMT2A (NM_001197104:c.10835 + 1 G > A), present in the twins (II:2, II:3) as well as in 
the mother (I:2) (Fig. 1a). The variant is not reported in public or in-house databases. The KMT2A nucleotide 
substitution is situated in the splice donor site of intron 28. In silico splicing prediction tools suggested complete 
loss of the splice donor site resulting in exon 28 skipping and an in-frame deletion of 81 bp, which was confirmed 
by analyses on cDNA derived from patients’ PBMCs (Fig. 1b). Mature KMT2A protein is physiologically cleaved 
in an N-terminal (KMT2A-N) and C-terminal (KMT2A-C) fragment, which together form a non-covalently 
associated complex (Fig. 1c)15, 18. Complex formation is necessary for stability and subnuclear localization of the 
protein18. The amino acids encoded by exon 28 are part of the interaction site between KMT2A-N and KMT2A-C 
(Fig. 1c)15. It has been shown that disrupting the interaction between the two fragments causes degradation of 
the KMT2A-N fragment and loss of protein function18. The KMT2A-N fragment was only very weakly detecta-
ble by western blot on PBMC lysates, however, and could therefore not be reliably interpreted (data not shown). 
Subsequent investigations in the mother demonstrated mild intellectual disability, undetectable serum IgM, and 
www.nature.com/scientificreports/
4Scientific RepoRts | 7: 3702  | DOI:10.1038/s41598-017-02434-4
Patient II:2 Patient II:3 Patient I:2
Value Reference range Value Reference range Value Reference range
White blood cells Age: 8 years Age: 8 years Age: 45 years
  Total leukocytes (no./µL) 11930 6000–14000 7340 6000–14000 7210 3650–9300
  Neutrophils (no./µL) 6980 2000–8000 3150 2000–8000 3450 1573–6100
  Lymphocytes (no./µL) 3990 1500–7500 3480 1500–7500 2870 1133–3105
    CD3+ T cells (no./µL) 2630 700–4200 2580 700–4200 2240 700–2100
      CD3+ CD4+ T helper cells (no./µL) 1600 300–2000 1640 300–2000 1120 300–1400
        CD45RA + naive CD4 + T cells (%) 82 46–77† 82 46–77† 44 NA
        CD45RO+ memory CD4+ T cells 
(%) 12 13–30
† 10 13–30† 50 NA
      CD3+ CD8+ T cytotoxic cells (no./
µL) 838 300–1800 800 300–1800 1060 200–1200
        CD45RA+ naive CD8+ T cells (%) 80 63–92† 69 63–92† 26 NA
        CD45RO+ memory CD8+ T cells 
(%) 12 4–21
† 10 4–21† 73 NA
    CD19+ B cells (no./µL) 798 200–1600 592 200–1600 287 100–500
      IgD + CD27- naive B cells (%) 96 47.3–77.0‡ 94 47.3–77.0‡ 88 48.4–79.7‡
      CD24 + + CD38++ transitional B 
cells (%) 19 4.6–8.3
‡ 10 4.6–8.3‡ 14 0.9–5.7‡
      IgD − CD27+ switched memory B 
cells (%) 1 10.9–30.4
‡ 1 10.9–30.4‡ 6 8.3–27.8‡
      IgD + CD27+ marginal zone B cells 
(%) 2 5.2–20.4
‡ 2 5.2–20.4‡ 3 7.0–23.8‡
      CD21low CD38low B cells (%) 2 2.3–10.0‡ 3 2.3–10.0‡ 2 1.6–10.0‡
    CD3 − CD56 + CD16+ NK cells 
(no./µL) 479 90–900 244 90–900 344 90–600
  Monocytes (no./µL) 690 700–1500 570 700–1500 780 247–757
  Eosinophils (no./µL) 220 200–500 100 200–500 80 28–273
  Basophils (no./µL) 30 10–100 20 10–100 10 6–50
Immunoglobulins* Age: 7 years Age: 3 years Age: 45 years
    IgG (g/L) 3.6 4.70–10.5 2.8 4.70–9.30 7.6 7.0–16.0
    IgG2 (g/L) 1.13 0.85–4.10 0.54 0.63–3.0 3.03 1.50–6.40
    IgG3 (g/L) 0.265 0.13–1.42 0.176 0.13–1.26 0.307 0.20–1.10
    IgM (g/L) <0.2 0.27–0.63 <0.2 0.27–0.57 <0.18 0.40–2.48
    IgA (g/L) 0.3 0.50–1.41 0.3 0.41–0.91 2.35 0.71–3.65
    IgE (kU/L) <4.4 0–90 <4.4 0–60 NA
Specific antibody responses* Age: 7 years Age: 3 years Age: 45 years
    S. pneumoniae polysaccharide IgG 
(Lab U) NA 9 ≥11: immune NA
    S. pneumoniae polysaccharide IgG: 
specific IgG response to 3 serotypes (8, 
9 N, 15B)
Insufficient 
antibody response
2x titer increase for at 
least 2 out of 3 serotypes NA
Good 
antibody 
response
2x titer increase for 
at least 2 out of 3 
serotypes
   Tetanus IgG (IU/mL) 0.01  ≥ 0.01: immune 0.03  ≥ 0.01: immune 0.50  ≥ 0.01: immune
   Rubella IgG (IU/mL) 12 >10: immune 44 >10: immune NA
   Measles IgG (mIU/mL) 350 >300: immune 1200 >300: immune NA
   Mumps IgG (Lab U/mL) 270 >500: immune 540 >500: immune NA
   Varicella Zoster IgG (mIU/mL) 620 >100: immune 1400 >100: immune NA
Lymphocyte proliferation assay Age: 3 years Age: 3 years
   Response to Concanavalin A Normal Compared to control Normal Compared to control NA
   Response to Phytohemagglutinin Normal Compared to control Normal Compared to control NA
   Response to Tetanus toxoid Normal Compared to control Moderately reduced Compared to control NA
Table 1. Routine immunological laboratory results of the family A patients with Wiedemann-Steiner syndrome. 
The most recent, comprehensive and representative laboratory results are shown for each patient. Patients II:2 
and II:3 were immunized according to the recommended Belgian childhood immunization schedule that, among 
others, included tetanus, measles, mumps, rubella and 7-valent conjugated pneumococcal vaccines. Patient I:2 
had received a tetanus booster vaccine within the last 10 years. A polysaccharide (unconjugated) pneumococcal 
vaccine was given to patients II:2 and I:2 at time of immunological evaluation; patient I:2 had never received 
a pneumococcal vaccine before then. Patients II:2 and II:3 were not vaccinated against varicella zoster virus 
but had chickenpox in early childhood. NA: not available. *Measured when not receiving immunoglobulin 
replacement therapy. †Reference values from Shearer et al.27. ‡Reference values from Piatosa et al.28.
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reduced switched memory B cells (Table 1). Taken together, the c.10835 + 1 G > A variant in KMT2A indicates a 
molecular diagnosis of WSS in the twin brothers and their mother.
Targeted sequencing confirms the diagnosis of RS in family B. In family B, WES was unable to iden-
tify a potentially disease-causing variant. In 2015, biallelic mutations in RNU4ATAC were identified in patients 
with RS8. Since RNU4ATAC is a noncoding snRNA gene, possible variants would have been missed with WES. 
Indeed, subsequent Sanger sequencing of RNU4ATAC revealed compound heterozygous variants in both siblings 
(c.13 C > T and c.116 A > T) that segregated in the parents (Fig. 2a). The c.13 C > T variant (rs559979281) had 
been previously reported in RS (Fig. 2c)8. The c.116 A > T variant has, to our knowledge, not yet been associated 
with human disease. The public database gnomAD (Genome Aggregation Database) contains two heterozygotes 
for the c.116 A > T variant (allele frequency of 0.00001531) but no homozygotes. Importantly, the c.116 A > T 
variant is located in a highly conserved position involved in splicing activity (Fig. 2c)8. Furthermore, position 116 
is immediately adjacent to the Sm protein-binding site, which is a highly conserved structural element essential 
in splicing activity and previously implicated in RS (Fig. 2c)8. Together, the RNU4ATAC genotype confirms the 
diagnosis of RS in the family B siblings.
Figure 2. Family B with RNU4ATAC-associated Roifman syndrome (RS). (a) Pedigree of family B. 
(b) Representative retinal images of the RS patients. Panel I, composite retinal image of fundus of left 
eye (LE) of patient II:1: note inferior outer retinal atrophy with greyish hue and intraretinal pigment 
migration of the spicular type in inferior retina; mottled aspect of retinal pigment epithelium, more 
pronounced in inferotemporal area. Panel II, blue light autofluorescence image of LE of patient II:1 showing 
hyperautofluorescent delineation of inferior atrophic zone, as well as superior to optic disc, illustrating more 
widespread disease than can be seen on white light fundoscopic image only. Panel III, similar image of right eye 
(RE) of patient II:1 as in Panel II. Panel IV, fundus picture of detail of superonasal midperiphery of RE of patient 
II:2. Despite a normal full-field flash electroretinography, recent fundus examination at 14 years of age showed 
a mild mottling of pigment epithelium suggestive of early stage retinal dystrophy. (c) U4atac snRNA showing 
structural elements, conserved positions and location of variants associated with RS (adapted from ref. 8). The 
here-reported variant that has not been previously associated with RS is shown in red.
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Immunological abnormalities in the WSS and RS patients. Because of the prominent immunodefi-
ciency in both sibling pairs, we performed flow cytometric analysis of B and T lymphocyte subsets as previously 
described19. Interestingly, all patients from families A and B had decreased circulating follicular helper T (cTfh) 
Patient II:1 Patient II:2
Value Reference range Value Reference range
White blood cells Age: 14 years Age: 11 years
  Total leukocyte count (no./µL) 7720 4500–12000 9800 4500–12000
  Neutrophils (no./µL) 5290 2500–8000 6080 2500–8000
  Lymphocytes (no./µL) 1190 1500–6500 2410 1500–6500
    CD3+ T cells (no./µL) 940 800–3500 1740 800–3500
      CD3 + CD4+ T helper cells (no./µL) 643 400–2100 1080 400–2100
        CD45RA+ naive CD4+ T cells (%) 55 33–66† 68 33–66†
        CD45RO+ memory CD4+ T cells (%) 38 18–38† 27 18–38†
      CD3 + CD8+ T cytotoxic cells (no./µL) 274 200–1200 603 200–1200
        CD45RA+ naive CD8+ T cells (%) 60 61–91† 67 61–91†
        CD45RO+ memory CD8+ T cells (%) 33 4–23† 22 4–23†
    CD19+ B cells (no./µL) 36 200–600 48 200–600
      IgD + CD27- naive B cells (%) 77 51.3–82.5‡ 70 51.3–82.5‡
      CD24 + + CD38++ transitional B cells (%) 15 1.4–13.0‡ 5 1.4–13.0‡
      IgD-CD27+ switched memory B cells (%) 9 8.7–25.6‡ 10 8.7–25.6‡
      IgD + CD27+ marginal zone B cells (%) 4 4.6–18.2‡ 1 4.6–18.2‡
      CD21low CD38low B cells (%) 22 2.7–8.7‡ 21 2.7–8.7‡
    CD3-CD56 + CD16+ NK cells (no./µL) 179 70–1200 554 70–1200
  Monocytes (no./µL) 910 500–1000 960 500–1000
  Eosinophils (no./µL) 290 100–500 230 100–500
  Basophils (no./µL) 20 10–100 90 10–100
Immunoglobulins* Age: 3 years Age: 6 years
   IgG (g/L) 3.8 4.7–9.3 4.4 4.7–10.5
   IgG2 (g/L) 0.53 0.63–3.0 0.49 0.85–4.1
   IgG3 (g/L) 0.021 0.13–1.26 0.242 0.13–1.42
   IgM (g/L) <0.2 0.27–0.57 0.3 0.27–0.63
   IgA (g/L) 0.3 0.41–0.91 <0.3 0.5–1.41
  IgE (kU/L) <4.4 0–60 <4.4 0–90
Isohemagglutinins* Age: 3 years
  ABO blood type O NA
  Anti-A IgM Negative Positive NA
  Anti-B IgM Negative Positive NA
Specific antibody responses* Age: 3 years Age: 6 years
  S. pneumoniae polysaccharide IgG (Lab U) <3  ≥ 11: immune 7  ≥ 11: immune
  Tetanus IgG (IU/mL) 0.03  ≥ 0.01: immune 1  ≥ 0.01: immune
  Rubella IgG (IU/mL) <8 >10: immune NA
  Measles IgG (mIU/mL) <150 >300: immune NA
  Mumps IgG (Lab U/mL) <230 >500: immune NA
  Varicella zoster IgG (mIU/mL) 360 >100: immune 1400 >100: immune
Lymphocyte proliferation assay Age: 9 years Age: 6 years
  Response to Concanavalin A Normal Compared to control Normal
Compared to 
control
  Response to Phytohemagglutinin Normal Compared to control Normal
Compared to 
control
  Response to Tetanus toxoid Normal Compared to control Normal
Compared to 
control
Table 2. Routine immunological laboratory results of the family B patients with Roifman syndrome. The most 
recent, comprehensive and representative laboratory results are shown for each patient. Both patients were 
immunized according to the recommended Belgian childhood immunization schedule that, among others, 
included tetanus, measles, mumps, rubella and 7-valent conjugated pneumococcal vaccines. A polysaccharide 
(unconjugated) pneumococcal vaccine was given at time of immunological evaluation. The patients were not 
vaccinated against varicella zoster virus but had chickenpox in early childhood. NA: not available. *Measured 
when not receiving immunoglobulin replacement therapy. †Reference values from Shearer et al.27. ‡Reference 
values from Piatosa et al.28.
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cells (Fig. 3a,b). Tfh cells play an essential role in the formation of antibody-producing plasma cells and mem-
ory B cells20. Furthermore, the two RS patients showed markedly reduced expression levels of B cell activating 
factor-receptor (BAFF-R), a receptor important in peripheral B cell survival (Fig. 3b)21. The WSS patients had 
normal BAFF-R levels (Fig. 3a). Expression of transmembrane activator and calcium modulator and cyclophilin 
ligand interactor (TACI), a receptor related to BAFF-R, was normal in both the WSS and RS patients (Fig. 3a,b)21. 
Clinical features†
18 published 
patients7, 9–14
Present study
Patient II:2 Patient II:3 Patient I:2
Gender 8 M, 10 F M M F
Age at last examination (years) 1–24 11 11 46
Short stature 18/18 + + +
Craniofacial features
   Microcephaly 2/7 − − −
   Mild macrocephaly NA + + −
 Hypertelorism, telecantus 9/17 + + +
   Down-slanted palpebral fissures 14/16 + + +
   Vertically narrow palpebral fissures 13/17 + + +
   Strabismus 4/17 − − −
   Thick eyebrows 14/17 + + +
   Wide nasal bridge 16/18 + + +
   Broad nasal tip 11/17 + + +
   Long philtrum 2/12 − − −
   Thin upper lip 6/12 + + +
   Low-set ears 2/12 + + +
   Abnormal dentition, hypodontia 5/9 − − −
   High palate 4/8 + + +
   Micrognathia 7/11 + + +
Musculoskeletal features
   Advanced bone age 1/16 NA NA NA
   Small hands and feet 5/17 + + +
   Fleshy hands and feet 3/7 + + +
   Clinodactyly 8/18 − + +
   Congenital hip dysplasia 2/17 − − −
   Muscular hypotonia 9/18 − − −
Dermatological features
   Thick hair 14/17 + + +
   Hypertrichosis cubiti 13/18 − − −
   Hypertrichosis back and/or lower limbs 16/18 − − −
Neurological features
   Developmental or psychomotor delay 18/18 − + NA
   Intellectual disability 16/17 + + +
   Autism 2/12 − − −
   Aggressive behavior 4/13 − − −
   Hyperactivity 2/12 − − −
   Seizures 1/7 − − −
Internal organ anomalies
   Cardiovascular anomalies 3/17 + + −
   Urogenital anomalies 4/17 − + +
   Intestinal anomalies 4/11 − − −
   Feeding difficulties 10/18 + + −
Immunodeficiency features
   Antibody deficiency 1/1 + + +
   Respiratory tract infections 2/17 + + +
   Urinary tract infections 4/18 − − −
   Bronchiectasis NA + + NA
Table 3. Comparison of the family A patients with published cases of KMT2A-associated Wiedemann-Steiner 
syndrome. NA: not available. †Not all clinical features have been ascertained in all previously published patients. 
Adapted from Stellacci et al.7.
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For all patients, the alterations in naive and memory lymphocyte subsets (Supplementary Figs 1–4) corresponded 
with those seen in the routine laboratory assessment (Table 1). Other examined B and T cell populations fell 
within the range of the age-matched healthy controls (Supplementary Figs 1–4).
Discussion
We report two sibling pairs with an early-onset CVID phenotype as primary and cardinal presentation of 
WSS and RS: recurrent sinopulmonary infections, panhypogammaglobulinemia, reduced polysaccharide vac-
cine responses, and aberrant peripheral B cell subsets1. Because extra-immunological features were initially 
subtle and only became conspicuous with age, the establishment of an accurate diagnosis was significantly 
delayed. Therefore, we recommend to proactively evaluate all paediatric patients with a CVID phenotype for 
extra-immunological syndromic features, especially when presenting at an early age. In particular, diagnostic 
workup should include evaluation by a clinical geneticist, in addition to orthopedic, cardiologic, neurologic, 
urogenital and ophthalmologic assessment. To reach a conclusive diagnosis, genetic testing should be performed, 
varying from targeted testing of a specific disease gene to WES. Here, the diagnosis of WSS in family A was only 
confirmed upon WES in affected family members7, 9. In family B on the other hand, WES failed to reveal the 
causal genetic defect because this was located in a noncoding gene8. Targeted testing of the known disease gene 
for RS allowed to identify the underlying mutations and to provide a definite diagnosis8. Of note, if WES does not 
identify a genetic defect and there is no known disease gene, whole genome sequencing should be undertaken22.
With this study, we extend the phenotypical and mutational spectrum of both KMT2A-associated WSS and 
RNU4ATAC-associated RS7–14. In family A, we identified a novel heterozygous splice site mutation in KMT2A 
Clinical features
6 published 
patients8
Present study
Patient 
II:1
Patient 
II:2
Gender 5 M, 1 F M F
Age at last examination (years) NA 17 14
Growth retardation
   Prenatal, intra-uterine growth retardation 6/6 NA NA
   Postnatal growth retardation 6/6 + +
Craniofacial features
   Mild microcephaly 5/6 + +
   Long philtrum 6/6 + +
   Thin upper lips 6/6 + +
   Narrow, tubular and upturned nose 6/6 + +
Ophthalmological features
   Retinal dystrophy 3/6 + +
Musculoskeletal features
   Epiphyseal dysplasia 6/6 + −
   Vertebral changes 3/6 + −
   Coxa vara NA + −
   Agenesis of anterior cruciate ligaments NA + −
   Agenesis of 12th ribs NA + −
   Short metacarpals 6/6 + −
   5th digit clinodactyly 4/6 − −
   Brachydactyly 6/6 + −
   Transverse palmar crease 5/6 − −
   Muscular hypotonia 5/6 − −
Neurological features
   Intellectual disability, cognitive delay 5/6 − −
   Sensorineural hearing loss 1/6 − −
Internal organ anomalies
   Noncompaction of the myocardium 1/6 − −
   Ventricular septum defect (VSD) 1/6 − −
   Lung hypoplasia NA − +
Immunodeficiency and atopic features
   Antibody deficiency 6/6 + +
   Hepatosplenomegaly 5/6 − −
   Bronchiectasis NA + +
   Eczema 3/6 − +
Table 4. Comparison of the family B patients with published cases of RNU4ATAC-associated Roifman 
syndrome. NA: not available.
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Figure 3. cTfh cells, BAFF-R expression and TACI expression in WSS and RS patients. (a) Family A patients 
with KMT2A-associated Wiedemann-Steiner syndrome (WSS). The twins (II:2, II:3) were 8 years old and the 
mother (I:2) was 43 years old at time of analysis. (b) Family B patients with RNU4ATAC-associated Roifman 
syndrome (RS). At time of analysis, the patients (II:1, II:2) were 14 and 11 years old, respectively. Flow 
cytometric immunophenotyping was performed on patients’ PBMCs in comparison with age-matched healthy 
controls (HC). T cells were gated as CD3+ and B cells as CD19+CD20+ in total PBMCs. Circulating follicular 
helper T (cTfh) cells were gated as CXCR5+CD45RO+ in CD4+ T cells. BAFF-R and TACI expression were 
measured on B cells. Relative mean fluorescence intensity (MFI) was calculated by dividing the MFI of the 
positive population by the MFI of the Fluorescence Minus One (FMO) population. Graphs of the HC groups 
represent mean ± standard deviation. BAFF-R: B cell activating factor-receptor, cTfh: circulating follicular 
helper T, expr: expression, TACI: transmembrane activator and calcium modulator and cyclophilin ligand 
interactor.
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causing in-frame deletion of exon 28. This deletion likely disrupts the stabilizing interaction site between the N- 
and C-terminal KMT2A fragments, resulting in loss of protein function18. So far, we were unable to confirm this 
on a protein level because the KMT2A-N protein fragment was not reliably detectable by western blot. Further 
studies on protein level are planned in the future. Family A is the first published kindred to show autosomal 
dominant transmission of KMT2A-associated WSS in multiple generations, as previously reported cases were 
either sporadic or parents were unavailable7. Remarkably, the characteristic hypertrichosis of elbows, back and/
or lower limbs was absent in the here-reported WSS patients, confirming previous literature that this feature 
may not be as pathognomonic as initially believed7, 9, 11, 12. Interestingly, KMT2A-associated WSS shows pheno-
typical overlap with Kabuki syndrome type 1 caused by heterozygous mutations in the related gene KMT2D23. 
Over 80% of patients with KMT2D-associated Kabuki syndrome develop defects in terminal B cell differentiation 
resulting in antibody deficiency23. Similarly, the here-described WSS patients demonstrated a block in terminal 
B cell differentiation evidenced by a relative increase in transitional and naive B cells and a relative decrease in 
switched memory B cells. Moreover, they had reduced levels of cTfh cells, which play a pivotal role in terminal B 
cell differentiation20. Decreased cTfh cells have, to our knowledge, not been previously reported in WSS or Kabuki 
syndrome. It would be interesting to investigate cTfh cells in additional patients with KMT2A-associated WSS and 
KMT2D-associated Kabuki syndrome as this may help elucidate the underlying pathophysiology of the antibody 
deficiency. In summary, humoral immune deficiency in patients with WSS reported by us and by Stellacci et al.7, 
and antibody deficiency in patients with heterozygous mutations in the related KMT2D gene23, strongly suggest a 
previously unknown role for KMT2A in B cell biology that may be related with T helper cell function.
In family B, we identified rare compound heterozygous mutations in the noncoding RNU4ATAC gene, of 
which one mutation (c.116 A > T) had not been associated with RS before8. Although it was not initially apparent, 
with time the boy showed typical features of RS including spondyloepiphyseal dysplasia and retinal dystrophy8. 
Curiously, he also demonstrated bilateral agenesis of the anterior cruciate ligaments and the 12th ribs, which are 
not typically seen in RS8. Spondyloepiphyseal or hip dysplasia have not yet been documented in the girl, currently 
14 years old, although she displays mild growth retardation. Only recently, she was found to have mild fundus 
abnormalities suggestive of early stage retinal dystrophy. Note that retinal dystrophy was already evident in her 
brother at 7 years of age. It would be interesting to investigate why the girl has a milder phenotype than her 
brother. Since U4atac snRNA plays a role in minor intron splicing, it would be valuable to conduct RNA sequenc-
ing analysis in the two siblings and check for possible differences in intron retention8. Detailed immunological 
workup in the RS patients revealed markedly decreased BAFF-R expression on B cells. To our knowledge, this 
finding has not been previously published. As BAFF-R signalling is important for survival of B cells in the periph-
eral blood, this may provide an important clue towards the B cell lymphopenia seen in RS patients21. Moreover, 
analogous to the WSS patients, the RS siblings demonstrated decreased levels of cTfh cells, which may further 
compromise B cell differentiation and antibody production20.
In conclusion, we here illustrate that a CVID phenotype can be the initial presentation of WSS and RS in early 
childhood while hallmark extra-immunological characteristics may be less prominent. With this, we highlight 
the importance of pursuing a genetic diagnosis in paediatric patients with an early-onset CVID phenotype, as this 
has important implications in terms of counselling, follow-up and screening for complications associated with 
the specific disorder.
Methods
Statement. All experiments and methods were carried out in accordance with relevant guidelines and reg-
ulations. The research protocol and all experimental protocols were approved by the ethical committee of Ghent 
University Hospital (2012/593). All reported subjects provided written informed consent for participation in the 
study, in accordance with the 1975 Helsinki Declaration.
Cytogenetic analyses. Microarray-based comparative genomic hybridization (array CGH) was performed 
on the affected sibling pairs of families A and B using the SurePrint G3 Human CGH Microarray Kit according 
to manufacturer’s instructions (Agilent Technologies). Results were analyzed with arrayCGHbase24. Karyotype 
analysis was performed on the family A twins using the conventional G-banding technique. To screen the fam-
ily A twins for submicroscopic subtelomeric rearrangements, multiplex ligation-dependent probe amplification 
(MLPA) analysis was performed using SALSA P070 and SALSA P036C probe mixes according to manufacturer’s 
instructions (MRC-Holland). To examine the family A twins for 22q11.2 deletion, fluorescence in situ hybridiza-
tion (FISH) analysis was performed using the DiGeorge Region Probe Set – LSI TUPLE 1 SpectrumOrange/LSI 
ARSA SpectrumGreen according to manufacturer’s instructions (Vyvis).
WES. Genomic DNA was isolated from whole blood leukocytes using the Puregene DNA isolation kit 
(Qiagen) according to manufacturer’s instructions. Whole exome enrichment was performed with the 
SureSelectXT Human All Exon V5 + UTRs kit (Agilent Technologies). Paired-end massively parallel sequencing 
(100 cycles) was performed on a NextSeq 500 (Illumina). Read mapping against the human genome reference 
sequence (NCBI, GRCh37), and post-mapping duplicate read removal, quality-based variant calling and coverage 
analysis were performed with CLC Genomics Workbench v6.0.4 (CLC bio). Sequencing coverage is summarized 
in Supplementary Table S1. Called variants with coverage ≥3 were annotated with Alamut Batch (Interactive 
Biosoftware). Only variants with population frequencies less than 10% were considered, according to public data-
bases NCBI dbSNP (http://www.ncbi.nlm.nih.gov/projects/SNP/), NHLBI Exome Sequencing Project (http://evs.
gs.washington.edu/EVS/), ExAC Browser (http://exac.broadinstitute.org/), and 1000 Genomes Project Browser 
(http://browser.1000genomes.org/). Variants were further prioritized based on allele frequency, functional pre-
diction scores, nucleotide conservation scores and biological relevance25. Both Mendelian and non-Mendelian 
inheritance patterns were taken into account. Afterwards, variants of interest were evaluated using Alamut Visual 
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mutation interpretation software v2.7 rev. 1 (Interactive Biosoftware), Ingenuity Variant Analysis (QIAGEN, 
2015 Release Spring), CADD scores v1.3 (http://cadd.gs.washington.edu/home), genome Aggregation Database 
(gnomAD) Browser (http://gnomad.broadinstitute.org), literature search, segregation analysis in available fam-
ily members, and frequency in an in-house database containing variants of more than 1000 exomes at time of 
analysis.
Sanger sequencing of genomic DNA. DNA templates (GRCh37/hg19) of KMT2A (NM_001197104) 
and RNU4ATAC (NR_023343) were obtained from UCSC Genome Browser (https://genome.ucsc.
edu). Primers for amplification and sequencing were designed with Primer3Plus26. For KMT2A exon 28 
and adjacent intron-exon borders (family A): forward primer 5′-CAACCCACAAGGGTGTCTTC-3′ 
and reverse primer 5′-GCCCGGCTAATTCTTTTTGT-3′. For the unique exon and intron-exon bor-
ders of RNU4ATAC (family B): forward primer 5′-TGGAGGCTGGAGGTAAGCTA-3′ and reverse primer 
5′-TGAGGTGCAAAGACCTACTGAA-3′. Genomic DNA was amplified by PCR using the specific prim-
ers and KAPA2G Robust Hotstart Ready Mix (KAPA Biosystems). PCR products were enzymatically purified 
with Exonuclease I and Antartic phosphatase (both New England BioLabs Inc.). Purified PCR products were 
sequenced using the BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) on a 3730xl DNA 
Analyzer (Applied Biosystems). Sequence reads were analyzed with SeqScape v2.5 (ThermoFisher Scientific).
RNA extraction, cDNA synthesis and confirmation of skipping of exon 28 in KMT2A. Total RNA 
was isolated from total PBMCs of all family A members and two control subjects by use of the RNeasy Plus Mini 
Kit (Qiagen) and reverse transcribed using the iScript cDNA synthesis kit (Bio-Rad), according to manufactur-
er’s instructions. The cDNA template (GRCh37/hg19) of KMT2A (NM_001197104) was obtained from UCSC 
Genome Browser (https://genome.ucsc.edu). Primers for amplification and sequencing of exon 28 and adjacent 
coding regions were designed with Primer3Plus26: forward primer 5′-AACCCAAACCAAAAACCAAAC-3′ and 
reverse primer 5′-CATCAGTGGGGAGCTGAAAT-3′. GAPDH was used as a reference target: forward primer 
5′-CAGCCTCAAGATCATCAGCA-3′ and reverse primer 5′-TGTGGTCATGAGTCCTTCCA-3′. PCR amplifi-
cation was performed by use of GoTaq Hot Start Colorless Master Mix (Promega). PCR products were analyzed 
on a 2% agarose gel in 1x TBE buffer (Quality Biological Inc). SYBR Safe (Invitrogen) signals were captured with 
a Gel Doc EZ Imager system (Bio-Rad). In addition, purified PCR products were Sanger sequenced using the 
BigDye Terminator v3.1 Cycle Sequencing kit (Applied Biosystems) on a 3130xL Genetic Analyzer (Applied 
Biosystems). Sequence reads were analyzed with SeqMan (DNAStar).
Flow cytometric analysis of PBMCs. Immunophenotyping was performed on PBMCs of patients and 
age-matched healthy controls. PBMCs were isolated from EDTA whole blood by Ficoll-Paque density gradient 
centrifugation and cryopreserved at −150 °C. Thawed PBMCs were stained with fixable viability dye 506 (eBio-
science) and fluorescently labeled monoclonal antibodies under saturation conditions as previously described19. 
Cells were acquired on an LSR Fortessa flow cytometer (BD Biosciences). Data were analyzed with FlowJo version 
X (Tree Star Inc.).
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